Affiliation:
1. Departments of Pathology
2. Epidemiology
3. Medicine, Roy J. and Lucille A. Carver College of Medicine and College of Public Health, University of Iowa, Iowa City, Iowa 52242
Abstract
ABSTRACT
Caspofungin is being used increasingly as therapy for invasive candidiasis. Prospective sentinel surveillance for emergence of in vitro resistance to caspofungin among invasive
Candida
spp. isolates is indicated. We determined the in vitro activity of caspofungin against 8,197 invasive (bloodstream or sterile-site) unique patient isolates of
Candida
collected from 91 medical centers worldwide from 1 January 2001 to 31 December 2004. We performed antifungal susceptibility testing according to the Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) M27-A2 method and used a 24-h prominent inhibition endpoint for determination of the MIC. Of 8,197 invasive
Candida
spp. isolates, species distribution was as follows: 54%
Candida albicans
, 14%
C. glabrata
, 14%
C. parapsilosis
, 11%
C. tropicalis
, 3%
C. krusei
, and 4% other
Candida
spp. Overall, caspofungin was very active against
Candida
(MIC
50
/MIC
90
, 0.03/0.25 μg/ml; 98.2% were inhibited at a MIC of ≤0.5 μg/ml and 99.7% were inhibited at a MIC of ≤1 μg/ml). Results by species (expressed as MIC
50
/MIC
90
and the percentage inhibited at ≤1 μg/ml) were as follows:
C. albicans
, 0.03/0.06, 99.9;
C. glabrata
, 0.03/0.06, 99.9;
C. parapsilosis
, 0.5/0.5, 99.0;
C. tropicalis
, 0.03/0.06, 99.7;
C. krusei
, 0.12/0.5, 99.0; and
C. guilliermondii
, 0.5/1, 94.4. Of the 25 isolates with caspofungin MICs of >1 μg/ml, 12 isolates were
C. parapsilosis
, 6 isolates were
C. guilliermondii
, 2 isolates were
C. rugosa
, and 1 isolate each was
C. albicans
,
C. glabrata
,
C. krusei
,
C. lusitaniae
, and
C. tropicalis
. There was no significant change in caspofungin activity over the 4-year study period. Likewise, there was no difference in activity by geographic region. Caspofungin has excellent in vitro activity against invasive clinical isolates of
Candida
from centers worldwide. Our prospective sentinel surveillance reveals no evidence of emerging caspofungin resistance among invasive clinical isolates of
Candida
.
Publisher
American Society for Microbiology
Reference28 articles.
1. Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases
2. Influences of Methodological Variables on Susceptibility Testing of Caspofungin against
Candida
Species and
Aspergillus fumigatus
3. Deresinksi, S. C., and D. A. Stevens. 2003. Caspofungin. Clin. Infect. Dis.36:1445-1457.
4. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors
5. Hazen, K. C., and S. A. Howell. 2003. Candida, Cryptococcus, and other yeasts of medical importance, p. 1693-1711. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. A. Pfaller, and R. J. Yolken (ed.), Manual of clinical microbiology, 8th ed. ASM Press, Washington, D.C.
Cited by
164 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献